Delfi Diagnostics
Delfi Diagnostics detects cancer early, when it is most curable, using high-precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. The company was founded in 2019 and is based in Baltimore, Maryland.
Last updated on
About Delfi Diagnostics
Founded
2019Estimated Revenue
$1M-$10MEmployees
51-250Funding / Mkt. Cap
$331MCategory
Sector
Health CareIndustry Group
Pharmaceuticals, Biotechnology & Life SciencesIndustry
BiotechnologyLocation
City
BaltimoreState
MarylandCountry
United StatesDelfi Diagnostics
Find your buyer within Delfi Diagnostics